Nektar Therapeutics | NKTR - 市值



金融业
股票价格
USD 37.72
资产
USD 763.27M
现金及等价物
USD 149.58M
销售成本
USD 4.44M
流动资产
USD 589.04M
流动负债
USD 57.71M
债务
USD 0
股息收益率
0
EBIT
USD -38.26M
EBITDA
USD -38.9M
员工
137
EPS每股收益
USD -1.78
股本和储备
USD 576.22M
销售毛利
USD 10.86M
债务利息支出
USD 7.94M
利息收入
USD -0.18
贷款资金
USD 60.27M
市值
USD 7.05B
净收入
USD -44.9M
营业费用
USD 49.12M
营业利润
USD -38.26M
普通股股本
USD 29.47M
税前利润
USD -43.09M
销售收入
USD 10.86M
销售和管理费用
USD 11.87M
股票
USD 14.46M
贸易债权人
USD 10.03M
应收帐款人
USD 3.6M


市值 更改 日
ALKERMES USD 8.73B 2.85B 2026-06
Alterity Therapeutics Limited AUD 39M 17M 2026-09
Amgen USD 195.44B 5.55B 2026-06
Baxter International USD 11.01B 2.34B 2026-06
BioCryst Pharmaceuticals USD 2.54B 880M 2026-06
Biogen USD 31.9B 5B 2026-06
Bristol-Myers Squibb USD 117.66B 6.17B 2026-06
Cara Therapeutics USD 30M 336M 2026-03
Cipla INR 1.18T 194.93B 2026-06
Dr.Reddys Laboratories INR 1.13T 85.62B 2026-06
Eisai JPY 1.2T 219.32B 2026-06
Eli Lilly USD 1.13T 260.54B 2026-06
Exelixis USD 13.54B 2.65B 2026-06
Gilead Sciences USD 156.86B 16.13B 2026-06
GlaxoSmithKline GBP 80.14B 3.66B 2026-06
Halozyme Therapeutics USD 9.28B 1.63B 2026-06
Incyte USD 22.65B 3.92B 2026-06
Ionis Pharmaceuticals USD 13.1B 642M 2026-06
Karyopharm Therapeutics USD 126M 9M 2026-03
MacroGenics USD 184M 82M 2026-03
Merck USD 317.37B 20.27B 2026-06
Nektar Therapeutics USD 2.12B 1.26B 2026-03
Neurocrine Biosciences USD 16.95B 3.7B 2026-06
Novartis USD 240.59B 67.17B 2026-06
Pfizer USD 138.44B 15.37B 2026-06
Roche Holding CHF 270B 3.66B 2026-06
Sarepta Therapeutics USD 1.9B 388M 2026-06
Takeda JPY 8.2T 809.7B 2026-06
Teva Pharmaceutical Industries USD 114.54B 80.27B 2026-06
Xencor USD 1.19B 301M 2026-06